logo-loader

Neurotech International bags $4M to commercialise autism device

Published: 22:41 16 Oct 2017 BST

human brain
Mente Autism helps relax the minds of children

Neurotech International Ltd (ASX:NTI) has successfully raised $4 million via a placement of shares at $0.20 each to drive its ongoing commercialisation of the Mente Autism device.

The Australian medical device company operates through its wholly-owned, Malta-based subsidiary AAT Research Limited.

Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of autism.

Mente Autism is a clinical-quality electroencephalography (EEG) device that uses neurofeedback technology to help children with Autism Spectrum Disorder (ASD).

The funds raised will be used for further product enhancements, manufacturing and purchase of additional inventory, and to investigate potential strategic initiatives.

Autism spectrum disorder is a developmental disability caused by differences in the brain.

Designed for home use, Mente Autism helps relax the minds of children on the spectrum, which in turns helps them to focus better and engage positively with their environment.

Neurotech is also pursuing further distributorships, complete its trial and make ongoing improvements to the Mente Autism device.

The company’s share price increased circa 11% during the past one month, closing at $0.205 on Monday.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

2 hours, 24 minutes ago